Design

This investigator-initiated study is a factorial, multicentre, randomised controlled trial.
11,140 participants have been recruited and randomised to either a fixed low-dose perindopril-indapamide combination or matching placebo, and to either an intensive modified-release gliclazide-based glucose lowering regimen or standard guidelines-based glucose lowering therapy. Follow-up will be for an average of 5-6 years.

The ADVANCE Study Design

The primary outcomes will be major macrovascular complications (stroke and heart attack) and major microvascular complications (eye and renal disease).

Organisation

The study organisation structure is shown below. The Management Committee has overall scientific responsibility for the study, which is managed by an International Coordinating Centre in Sydney (The George Institute for Global Health),and five regional coordinating centres in Beijing, London, Melbourne, Montreal and Utrecht.
Each regional coordinating centre is responsible for the clinical sites within one or more countries.

The ADVANCE Study Committee